organization · Reporting owner
Flagship Pioneering Fund VII, L.P.
Disclosed activity across 6 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Evelo Biosciences, Inc.EVLO · Entity 108468 | 10% owner | July 11, 2023 | July 13, 2023 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director · 10% owner | January 13, 2026 | January 15, 2026 |
| Generate Biomedicines, Inc.GENB · Entity 1553 | 10% owner | February 26, 2026 | March 02, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | 10% owner | February 27, 2023 | February 27, 2023 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | 10% owner | February 12, 2024 | February 14, 2024 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | 10% owner | July 05, 2022 | July 07, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Evelo Biosciences, Inc.
Report date July 11, 2023 · Filed July 13, 2023
Jointly reported with Flagship Ventures Fund IV General Partner LLC, Flagship Ventures Fund IV, L.P., Nutritional Health LTP Fund General Partner LLC, Nutritional Health LTP Fund, L.P., Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV, L.P. | 1,461,795 |
Reported balance
After 2023-07-11 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,461,795 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 1,493,241 |
Reported balance
After 2023-07-11 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-11 · Purchase · Acquired 1,082,251 · Balance 1,493,241 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 3,931,685 |
Reported balance
After 2023-07-11 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2023-07-11 · Purchase · Acquired 3,246,753 · Balance 3,931,685 F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund IV-Rx, L.P. | 94,371 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 94,371 F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Opportunities Fund I, L.P. | 274,766 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 274,766 F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs IV LLC | 34,219 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 34,219 F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs V LLC | 132,282 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 132,282 F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Ventures Fund V, L.P. | 210,064 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 210,064 F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship V VentureLabs Rx Fund, L.P. | 80,494 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 80,494 F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Side Fund, L.P. | 39,798 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · Balance 39,798 F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health Disruptive Innovation Fund, L.P. | 179,909 |
Reported balance
Holding disclosure · report date 2023-07-11 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 179,909 F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share.
F2: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F3: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F4: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F5: Shares held by Flagship Ventures Fund IV-Rx, L.P ("Flagship Fund IV-Rx"). Flagship Fund IV GP is the general partner of Flagship Fund IV-Rx. Each of the reporting persons except for Flagship Fund IV-Rx disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F6: Shares held by Flagship Ventures Opportunities Fund I, L.P. ("Flagship Opportunities I"). Flagship Ventures Opportunities Fund I General Partner LLC ("Flagship Opportunities GP") is the general partner of Flagship Opportunities I. Dr. Afeyan is the sole manager of Flagship Opportunities GP. Each of the reporting persons except for Flagship Opportunities I disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F7: Shares held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship Fund IV is the manager of VentureLabs IV. Each of the reporting persons except for VentureLabs IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F8: Shares held by Flagship VentureLabs V LLC ("VentureLabs V"). Flagship VentureLabs V Manager LLC ("VentureLabs V Manager") serves as manager of VentureLabs V. Flagship Pioneering is the manager of VentureLabs V Manager. Each of the reporting persons except for VentureLabs V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F9: Shares held by Flagship Ventures Fund V, L.P. ("Flagship Fund V"). Flagship Ventures Fund V General Partner LLC ("Flagship Fund V GP") is the general partner of Flagship Fund V. Dr. Afeyan serves as sole manager of Flagship Fund V. Each of the reporting persons except for Flagship Fund V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F10: Shares held by Flagship V VentureLabs Rx Fund, L.P. ("VentureLabs Rx V"). Flagship Fund V GP is the general partner of VentureLabs Rx V. Each of the reporting persons except for VentureLabs Rx V disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F11: Shares held by Nutritional Health Side Fund, L.P. ("Nutritional Health Side Fund"). Flagship Fund V GP is the general partner of Nutritional Health Side Fund. Each of the reporting persons except for Nutritional Health Side Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
F12: Shares held by Nutritional Health Disruptive Innovation Fund, L.P. ("Nutritional Innovation Fund"). Flagship Fund V GP is the general partner of Nutritional Innovation Fund. Each of the reporting persons except for Nutritional Innovation Fund disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Foghorn Therapeutics Inc.
Report date January 13, 2026 · Filed January 15, 2026
Jointly reported with Flagship Pioneering, LLC, Flagship Pioneering Fund VII General Partner LLC, Flagship Pioneering Special Opportunities Fund II General Partner LLC, Flagship Pioneering Special Opportunities Fund II, L.P., Flagship Ventures Fund V General Partner LLC, Flagship Ventures Fund V, L.P., Flagship Ventures Opportunities Fund I General Partner LLC, Flagship Ventures Opportunities Fund I, L.P., Afeyan Noubar
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2046-01-13 | IndirectBy Flagship Pioneering Fund VII, L.P. | 2,235,468 |
Reported balance
After 2026-01-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-13 · Grant · Acquired 2,235,468 · Balance 2,235,468 F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 1 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $13.42 · Expires 2027-06-30 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series 2 Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $20.13 · Expires 2030-12-31 | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,117,734 |
Reported balance
After 2026-01-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-13 · Grant · Acquired 1,117,734 · Balance 1,117,734 F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants.
F2: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F3: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism.
Generate Biomedicines, Inc.
Report date February 26, 2026 · Filed March 02, 2026
Jointly reported with Afeyan Noubar, Flagship VentureLabs VI LLC, Flagship Pioneering Fund VI, L.P., Nutritional Health LTP Fund, L.P., Flagship Pioneering Special Opportunities Fund II, L.P., FPN II, L.P.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VI, L.P. | 12,723,940 |
Reported balance
After 2026-03-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-03-02 · Conversion · Acquired 12,723,940 · Balance 12,723,940 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 15,264,724 |
Last balance in matching sequence
After 2026-03-02 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 2 · 2026-03-02 · Conversion · Acquired 13,702,224 · Balance 13,702,224 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 6 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 15,264,724 F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Nutritional Health LTP Fund, L.P. | 987,491 |
Reported balance
After 2026-03-02 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-03-02 · Conversion · Acquired 987,491 · Balance 987,491 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 2,777,752 |
Reported balance
After 2026-03-02 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy FPN II, L.P. | 4,340,252 |
Last balance in matching sequence
After 2026-03-02 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 5 · 2026-03-02 · Conversion · Acquired 2,777,752 · Balance 2,777,752 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Row 7 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 4,340,252 F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Pioneering Medicines 02, LLC | 1,562,500 |
Reported balance
After 2026-03-02 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2026-03-02 · Purchase · Acquired 1,562,500 · Balance 1,562,500 F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-02-25 | Direct | 29,561 |
Reported balance
After 2026-02-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-02-26 · Grant · Acquired 29,561 · Balance 29,561 F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-03-02 · Conversion · Disposed 18,483,785 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-03-02 · Conversion · Disposed 17,016,215 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy Nutritional Health LTP Fund, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-03-02 · Conversion · Disposed 1,500,000 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VI, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-03-02 · Conversion · Disposed 843,881 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-03-02 · Conversion · Disposed 2,953,586 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Fund VII, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-03-02 · Conversion · Disposed 2,531,644 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy Flagship Pioneering Special Opportunities Fund II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2026-03-02 · Conversion · Disposed 1,265,822 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectBy FPN II, L.P. | 0 |
Reported balance
After 2026-03-02 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2026-03-02 · Conversion · Disposed 2,109,704 · Balance 0 F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Flagship VentureLabs VI, LLC | 25,016,458 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · Balance 25,016,458 F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F2: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date.
F3: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F4: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F5: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F6: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F7: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F8: Securities held by Flagship VentureLabs VI LLC ("VentureLabs VI"). Flagship VentureLabs VI Manager LLC ("VentureLabs VI Manager") is the manager of VentureLabs VI. Flagship Pioneering is the manager of VentureLabs VI Manager. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
F9: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date.
Omega Therapeutics, Inc.
Report date February 27, 2023 · Filed February 27, 2023
Jointly reported with Flagship Pioneering Fund VII General Partner LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 1,329,324 |
Reported balance
Holding disclosure · report date 2023-02-27 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,329,324 F1: On February 27, 2023, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,329,324 shares of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023. F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 27, 2023, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") purchased 1,329,324 shares of the Issuer's Common Stock in a registered direct offering at a price of $5.78 per share pursuant to a Securities Purchase Agreement dated February 22, 2023.
F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Sana Biotechnology, Inc.
Report date February 12, 2024 · Filed February 14, 2024
Jointly reported with Flagship Pioneering Fund VII General Partner LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre-Funded Warrants to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectBy Flagship Pioneering Fund VII, L.P. | Not disclosed |
Reported balance
Holding disclosure · report date 2024-02-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date. F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 12, 2024, pursuant to an underwritten public offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired pre-funded warrants to purchase 2,727,272 shares of Common Stock (the "Pre-Funded Warrants") at a purchase price of $5.4999 per Pre-Funded Warrant. The Pre-Funded Warrants do not have an expiration date.
F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.
Seres Therapeutics, Inc.
Report date July 05, 2022 · Filed July 07, 2022
Jointly reported with Flagship Pioneering Fund VII General Partner LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Flagship Pioneering Fund VII, L.P. | 5,825,495 |
Reported balance
Holding disclosure · report date 2022-07-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 5,825,495 F1: On July 5, 2022, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 5,825,495 shares of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share. F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 5, 2022, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 5,825,495 shares of the Issuer's Common Stock in a registered direct offering at a price of $3.15 per share.
F2: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Flagship Fund VII GP. Dr. Afeyan is the Chief Executive Officer, sole shareholder and director of Flagship Pioneering. Each of the reporting persons except Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 20 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 19 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries C Preferred Stock · Derivative | 2,531,644 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 18 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,666,651 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,109,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 17 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,388,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 2,953,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 16 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,944,427 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 1,265,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 15 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 833,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries B Preferred Stock · Derivative | 843,881 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 14 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 555,550 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 1,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 13 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 0 Underlying: Common Stock · 987,491 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 17,016,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 12 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 0 Underlying: Common Stock · 11,202,248 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionSeries A Preferred Stock · Derivative | 18,483,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 11 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 0 Underlying: Common Stock · 12,168,390 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.exercise_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F1 · derivative.expiration_date: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 8 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Pioneering Medicines 02, LLC Disclosed balance after: 1,562,500 F7 · ownership.nature: Securities held by Pioneering Medicine 02, LLC ("PM02"). Charles R. Carelli, Jr., Chief Financial Officer of Flagship Pioneering, is the sole manager of PM02, and Flagship Fund VII is its majority equity holder. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 7 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 4,340,252 F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 6 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 15,264,724 F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 5 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By FPN II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F6 · ownership.nature: Securities held by FPN II, L.P. ("FPN II Fund"). FPN General Partner LLC ("FPN GP") is the general partner of FPN II Fund. Flagship Pioneering is the manager of FPN GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 2,777,752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 4 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Special Opportunities Fund II, L.P. Disclosed balance after: 2,777,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F5 · ownership.nature: Securities held by Flagship Pioneering Special Opportunities Fund II, L.P. ("Flagship Opportunities Fund II"). Flagship Pioneering Special Opportunities Fund II General Partner LLC ("Flagship Opportunities Fund II GP") is the general partner of Flagship Opportunities Fund II. Flagship Pioneering is the manager of Flagship Opportunities Fund II GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 987,491 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 3 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 987,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F4 · ownership.nature: Securities held by Nutritional Health LTP Fund, L.P. ("Nutritional LTP"). Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering is the manager of Nutritional LTP GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 13,702,224 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 2 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 13,702,224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F3 · ownership.nature: Securities held by Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII"). Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| March 02, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | ConversionCommon Stock | 12,723,940 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · nonDerivative · entry 1 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VI, L.P. Disclosed balance after: 12,723,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Securities held by Flagship Pioneering Fund VI, L.P. ("Flagship Fund VI"). Flagship Pioneering Fund VI General Partner LLC ("Flagship Fund VI GP") is the general partner of Flagship Fund VI. Flagship Pioneering, LLC ("Flagship Pioneering") is the manager of Flagship Fund VI GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. F2 · ownership.nature: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted into shares of the Issuer's Common Stock on a one-for-1.5190 basis upon the closing of the Issuer's initial public offering on March 2, 2026. The Preferred Stock had no expiration date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 17:42 UTC | Generate Biomedicines, Inc. GENB · Entity 1553 | GrantStock Option (Right to Buy) · Derivative | 29,561 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-085855 · ownership.xml · derivative · entry 10 AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Flagship VentureLabs VI LLC · CIK 0001725008 · 10% owner Flagship Pioneering Fund VI, L.P. · CIK 0001716926 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · 10% owner FPN II, L.P. · CIK 0001918834 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,561 Underlying: Common Stock · 29,561 shares Expires 2036-02-25 F9 · derivative.exercise_date: The shares underlying this option shall vest in full on February 19, 2027, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 2 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $20.13 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 3 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2030-12-31 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantSeries 1 Warrants to purchase Common Stock · Derivative | 1,117,734 | Not disclosed Strike: $13.42 | Not disclosed |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 2 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 1,117,734 Underlying: Common Stock · 1,117,734 shares Expires 2027-06-30 F3 · derivative.exercise_price: The Series Warrants are exercisable at an initial price of $13.42 per Series 1 Warrant and $20.13 per Series 2 Warrant. Subject to certain exclusions, if prior to June 30, 2027, the Company issues capital stock or securities convertible into or exercisable for capital stock in one or more related transactions primarily for capital raising at a weighted-average common stock equivalent price (the "Weighted-Average Price") below $13.42 per share, the exercise price of a Series Warrant shall reset upon exercise to the midpoint between the initial price and the lowest such Weighted-Average Price, but not below $6.71 per share. The exercise price may be adjusted only once pursuant to this mechanism. F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 17:00 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantPre-Funded Warrants to purchase Common Stock · Derivative | 2,235,468 | $6.71 Strike: $0.00 | $14,999,766.73 |
DisclosureSEC source: 0001193125-26-014218 · ownership.xml · derivative · entry 1 Flagship Pioneering, LLC · CIK 0001400240 · Director · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · Director · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II General Partner LLC · CIK 0001826217 · Director · 10% owner Flagship Pioneering Special Opportunities Fund II, L.P. · CIK 0001761283 · Director · 10% owner Flagship Ventures Fund V General Partner LLC · CIK 0001724575 · Director · 10% owner Flagship Ventures Fund V, L.P. · CIK 0001627639 · Director · 10% owner Flagship Ventures Opportunities Fund I General Partner LLC · CIK 0001725004 · Director · 10% owner Flagship Ventures Opportunities Fund I, L.P. · CIK 0001677345 · Director · 10% owner AFEYAN NOUBAR · CIK 0001222012 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 2,235,468 Underlying: Common Stock · 2,235,468 shares Expires 2046-01-13 F1 · price: On January 13, 2026, pursuant to a registered direct offering by the Issuer, Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired warrants to purchase an aggregate of 4,470,936 shares of Common Stock, consisting of (i) Pre-Funded Warrants to purchase 2,235,468 shares of Common Stock, (ii) Series 1 Warrants to purchase 1,117,734 shares of Common Stock and (iii) Series 2 Warrants to purchase 1,117,734 shares of Common Stock (together with the Series 1 Warrants, the "Series Warrants"). The securities were acquired for a purchase price of $6.7099 per Pre-Funded Warrant and accompanying Series Warrants. F2 · ownership.nature: Securities held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering, LLC (f/k/a Flagship Pioneering, Inc., "Flagship Pioneering") is the manager of Flagship Fund VII GP. Noubar B. Afeyan, Ph.D. is the ultimate control person of Flagship Pioneering. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 3,246,753 | $2.31 | $7,499,999.43 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 3 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Pioneering Fund VII, L.P. Disclosed balance after: 3,931,685 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F4 · ownership.nature: Shares held by Flagship Fund VII. Flagship Pioneering Fund VII General Partner LLC ("Flagship Fund VII GP") is the general partner of Flagship Fund VII. Flagship Pioneering is the manager of Flagship Fund VII GP. Each of the reporting persons except for Flagship Fund VII disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,082,251 | $2.31 | $2,499,999.81 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 2 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Nutritional Health LTP Fund, L.P. Disclosed balance after: 1,493,241 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F3 · ownership.nature: Shares held by Nutritional LTP. Nutritional Health LTP Fund General Partner LLC ("Nutritional LTP GP") is the general partner of Nutritional LTP. Flagship Pioneering, Inc. ("Flagship Pioneering") is the manager of Nutritional LTP GP. Dr. Afeyan is the Chief Executive Officer, director and sole stockholder of Flagship Pioneering. Each of the reporting persons except for Nutritional LTP disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
| July 11, 2023 Filed Jul 13, 2023 17:15 UTC | Evelo Biosciences, Inc. EVLO · Entity 108468 | PurchaseCommon Stock | 1,082,251 | $2.31 | $2,499,999.81 |
DisclosureSEC source: 0000950170-23-032871 · ownership.xml · nonDerivative · entry 1 Flagship Ventures Fund IV General Partner LLC · CIK 0001508051 · 10% owner Flagship Ventures Fund IV, L.P. · CIK 0001503559 · 10% owner Nutritional Health LTP Fund General Partner LLC · CIK 0001780951 · 10% owner Nutritional Health LTP Fund, L.P. · CIK 0001780956 · 10% owner Flagship Pioneering Inc. · CIK 0001400240 · 10% owner Flagship Pioneering Fund VII General Partner LLC · CIK 0001805917 · 10% owner Flagship Pioneering Fund VII, L.P. · CIK 0001805916 · 10% owner AFEYAN NOUBAR · CIK 0001222012 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Flagship Ventures Fund IV, L.P. Disclosed balance after: 1,461,795 F1 · kind: On July 11, 2023, Flagship Ventures Fund IV, L.P. ("Flagship Fund IV"), Nutritional Health LTP Fund, L.P. ("Nutritional LTP") and Flagship Pioneering Fund VII, L.P. ("Flagship Fund VII") acquired 1,082,251 shares, 1,082,251 shares and 3,246,753 shares, respectively, of the Issuer's Common Stock in a private placement at a price of $2.31 per share. F2 · ownership.nature: Shares held by Flagship Fund IV. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of Flagship Fund IV. Noubar B. Afeyan, Ph.D. ("Dr. Afeyan") is the sole manager of Flagship Fund IV GP. Each of the reporting persons except for Flagship Fund IV disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.